WGU D027 ADVANCED PATHOPHARMACOLOGICAL
FOUNDATIONS MOCK EXAM, WESTERN GOVERNORS
UNIVERSITY NURSING PROGRAMS - (70 QUESTIONS) UP-TO-
DATE ACTUAL EXAM QUESTIONS AND 100% ACCURATE
SOLUTIONS | VERIFIED ANSWERS - INSTANT PDF DOWNLOAD
Examiner/Administrator: Western Governors University (WGU)
Candidate Name: ____________________________________________
Candidate ID: ________________________________________________
Date: ________________________________________________________
Testing Location: _____________________________________________
Time Allocation: 120 Minutes
Total Questions: 70
Instructions:
• Read each question carefully before selecting the best answer.
• All questions are multiple-choice with one correct answer.
• Clinical reasoning and pharmacological application are heavily emphasized.
• No external materials permitted unless specified by the proctor.
• Manage your time effectively to complete all questions.
Core Competency Domains:
• Advanced Pharmacokinetics & Pharmacodynamics
• Cardiovascular and Renal Pharmacology
• Endocrine and Metabolic Disorders
• Neurological and Psychiatric Pharmacology
• Immunological and Infectious Disease Management
• Clinical Decision-Making and Patient Safety
This assessment evaluates advanced integration of pharmacological
principles in clinical nursing practice. Candidates are expected to apply
knowledge of drug mechanisms, interactions, contraindications, and patient-
specific variables to complex clinical scenarios. The exam reflects
competency-based evaluation aligned with modern nursing standards and
, emphasizes safe medication administration, critical thinking, and evidence-
based care.
This is an original mock examination designed for educational purposes. It is
not affiliated with or derived from actual proprietary examination content but
reflects the style and rigor of the official assessment.
Q1. A patient with chronic kidney disease (CKD stage 4) is prescribed a renally
excreted antibiotic. Which pharmacokinetic principle must be prioritized when
adjusting the dosage?
A. Increased hepatic metabolism
B. Reduced plasma protein binding
C. Decreased renal clearance
D. Increased bioavailability
Correct Answer: C. Decreased renal clearance
Explanation: In CKD, renal clearance is reduced, leading to drug
accumulation and toxicity if doses are not adjusted. A is incorrect because
hepatic metabolism is not the primary concern. B is incorrect since protein
binding changes are secondary. D is incorrect because bioavailability is not
significantly altered in CKD.
Q2. A patient taking warfarin begins therapy with a broad-spectrum antibiotic.
What is the most likely outcome?
A. Decreased INR due to enzyme induction
B. Increased INR due to reduced vitamin K synthesis
C. No change in anticoagulation
D. Increased clotting risk
Correct Answer: B. Increased INR due to reduced vitamin K synthesis
Explanation: Antibiotics reduce gut flora responsible for vitamin K
production, enhancing warfarin effect and increasing INR. A is incorrect
,because antibiotics typically inhibit rather than induce enzymes. C and D are
incorrect due to enhanced anticoagulation risk.
Q3. A beta-blocker is prescribed to a patient with asthma. Which effect is most
concerning?
A. Bradycardia
B. Bronchoconstriction
C. Hypotension
D. Hyperglycemia
Correct Answer: B. Bronchoconstriction
Explanation: Non-selective beta-blockers block β2 receptors, causing
bronchoconstriction. A and C are expected but manageable. D is not a primary
concern.
Q4. A patient receiving digoxin presents with nausea and visual disturbances.
What electrolyte imbalance is most likely contributing?
A. Hyperkalemia
B. Hypokalemia
C. Hypercalcemia
D. Hyponatremia
Correct Answer: B. Hypokalemia
Explanation: Hypokalemia increases digoxin toxicity by enhancing binding
to Na⁺/K⁺ ATPase. A is incorrect as hyperkalemia reduces digoxin binding. C
and D are less directly related.
Q5. A nurse administers morphine to a patient with respiratory depression.
Which receptor activity explains this adverse effect?
A. Delta receptor activation
B. Kappa receptor activation
C. Mu receptor activation
D. NMDA receptor blockade
, Correct Answer: C. Mu receptor activation
Explanation: Mu receptor activation leads to respiratory depression. Delta
and kappa receptors have less impact on respiration. NMDA blockade is
unrelated.
Q6. A patient with hypertension is prescribed an ACE inhibitor. Which lab
value should be closely monitored?
A. Sodium
B. Potassium
C. Calcium
D. Magnesium
Correct Answer: B. Potassium
Explanation: ACE inhibitors can cause hyperkalemia. A, C, and D are less
directly affected.
Q7. A drug exhibits first-pass metabolism. What does this imply?
A. Drug is eliminated in kidneys first
B. Drug is metabolized in the liver before systemic circulation
C. Drug bypasses hepatic metabolism
D. Drug has increased bioavailability
Correct Answer: B. Drug is metabolized in the liver before systemic
circulation
Explanation: First-pass effect reduces bioavailability via hepatic
metabolism. A, C, and D are incorrect interpretations.
Q8. A patient taking SSRIs develops serotonin syndrome. Which symptom is
expected?
A. Hypothermia
B. Muscle rigidity
FOUNDATIONS MOCK EXAM, WESTERN GOVERNORS
UNIVERSITY NURSING PROGRAMS - (70 QUESTIONS) UP-TO-
DATE ACTUAL EXAM QUESTIONS AND 100% ACCURATE
SOLUTIONS | VERIFIED ANSWERS - INSTANT PDF DOWNLOAD
Examiner/Administrator: Western Governors University (WGU)
Candidate Name: ____________________________________________
Candidate ID: ________________________________________________
Date: ________________________________________________________
Testing Location: _____________________________________________
Time Allocation: 120 Minutes
Total Questions: 70
Instructions:
• Read each question carefully before selecting the best answer.
• All questions are multiple-choice with one correct answer.
• Clinical reasoning and pharmacological application are heavily emphasized.
• No external materials permitted unless specified by the proctor.
• Manage your time effectively to complete all questions.
Core Competency Domains:
• Advanced Pharmacokinetics & Pharmacodynamics
• Cardiovascular and Renal Pharmacology
• Endocrine and Metabolic Disorders
• Neurological and Psychiatric Pharmacology
• Immunological and Infectious Disease Management
• Clinical Decision-Making and Patient Safety
This assessment evaluates advanced integration of pharmacological
principles in clinical nursing practice. Candidates are expected to apply
knowledge of drug mechanisms, interactions, contraindications, and patient-
specific variables to complex clinical scenarios. The exam reflects
competency-based evaluation aligned with modern nursing standards and
, emphasizes safe medication administration, critical thinking, and evidence-
based care.
This is an original mock examination designed for educational purposes. It is
not affiliated with or derived from actual proprietary examination content but
reflects the style and rigor of the official assessment.
Q1. A patient with chronic kidney disease (CKD stage 4) is prescribed a renally
excreted antibiotic. Which pharmacokinetic principle must be prioritized when
adjusting the dosage?
A. Increased hepatic metabolism
B. Reduced plasma protein binding
C. Decreased renal clearance
D. Increased bioavailability
Correct Answer: C. Decreased renal clearance
Explanation: In CKD, renal clearance is reduced, leading to drug
accumulation and toxicity if doses are not adjusted. A is incorrect because
hepatic metabolism is not the primary concern. B is incorrect since protein
binding changes are secondary. D is incorrect because bioavailability is not
significantly altered in CKD.
Q2. A patient taking warfarin begins therapy with a broad-spectrum antibiotic.
What is the most likely outcome?
A. Decreased INR due to enzyme induction
B. Increased INR due to reduced vitamin K synthesis
C. No change in anticoagulation
D. Increased clotting risk
Correct Answer: B. Increased INR due to reduced vitamin K synthesis
Explanation: Antibiotics reduce gut flora responsible for vitamin K
production, enhancing warfarin effect and increasing INR. A is incorrect
,because antibiotics typically inhibit rather than induce enzymes. C and D are
incorrect due to enhanced anticoagulation risk.
Q3. A beta-blocker is prescribed to a patient with asthma. Which effect is most
concerning?
A. Bradycardia
B. Bronchoconstriction
C. Hypotension
D. Hyperglycemia
Correct Answer: B. Bronchoconstriction
Explanation: Non-selective beta-blockers block β2 receptors, causing
bronchoconstriction. A and C are expected but manageable. D is not a primary
concern.
Q4. A patient receiving digoxin presents with nausea and visual disturbances.
What electrolyte imbalance is most likely contributing?
A. Hyperkalemia
B. Hypokalemia
C. Hypercalcemia
D. Hyponatremia
Correct Answer: B. Hypokalemia
Explanation: Hypokalemia increases digoxin toxicity by enhancing binding
to Na⁺/K⁺ ATPase. A is incorrect as hyperkalemia reduces digoxin binding. C
and D are less directly related.
Q5. A nurse administers morphine to a patient with respiratory depression.
Which receptor activity explains this adverse effect?
A. Delta receptor activation
B. Kappa receptor activation
C. Mu receptor activation
D. NMDA receptor blockade
, Correct Answer: C. Mu receptor activation
Explanation: Mu receptor activation leads to respiratory depression. Delta
and kappa receptors have less impact on respiration. NMDA blockade is
unrelated.
Q6. A patient with hypertension is prescribed an ACE inhibitor. Which lab
value should be closely monitored?
A. Sodium
B. Potassium
C. Calcium
D. Magnesium
Correct Answer: B. Potassium
Explanation: ACE inhibitors can cause hyperkalemia. A, C, and D are less
directly affected.
Q7. A drug exhibits first-pass metabolism. What does this imply?
A. Drug is eliminated in kidneys first
B. Drug is metabolized in the liver before systemic circulation
C. Drug bypasses hepatic metabolism
D. Drug has increased bioavailability
Correct Answer: B. Drug is metabolized in the liver before systemic
circulation
Explanation: First-pass effect reduces bioavailability via hepatic
metabolism. A, C, and D are incorrect interpretations.
Q8. A patient taking SSRIs develops serotonin syndrome. Which symptom is
expected?
A. Hypothermia
B. Muscle rigidity
